From standardized medicines to public oversight

Drug regulation developed through overlapping efforts to establish what medicines contained, control their manufacture and sale, evaluate therapeutic claims, and investigate harm. These were different problems: a preparation could meet a standard of composition without having demonstrated clinical benefit. The history therefore involves changing expectations about evidence as well as expanding government authority.

In the United States, physicians established the U.S. Pharmacopeia in 1820, while the Drug Importation Act of 1848 required inspection to exclude adulterated imported drugs. The 1902 Biologics Control Act addressed the purity and safety of vaccines, serums and related products. In 1906, federal legislation prohibited interstate commerce in adulterated or misbranded drugs. These measures illustrate the gradual construction of oversight rather than a single founding moment. FDA’s historical chronology identifies these distinct stages.

For the professional setting in which medicines were prepared and supplied, see the history of pharmacy and apothecaries.

The sulfanilamide disaster and evidence before sale

In 1937, a liquid preparation called Elixir Sulfanilamide caused more than one hundred deaths in the United States. Its solvent, diethylene glycol, was poisonous. The manufacturer had assessed the preparation’s taste, appearance and fragrance but had not tested its toxicity. Existing federal law did not require such safety studies before a new drug reached patients.

The episode exposed a dangerous assumption: experience with a medicinal ingredient did not establish the safety of a different formulation. Recovering the product also required extensive investigation because distribution and patient records were incomplete. Safety depended on practical systems for tracing medicines as well as laboratory knowledge.

Reform proposals already existed; the disaster accelerated their enactment rather than creating the entire reform movement. The Federal Food, Drug, and Cosmetic Act of 1938 required evidence of safety before new drugs were marketed. Carol Ballentine’s FDA history documents both the poisoning and the limits of the earlier law.

Effectiveness becomes a regulatory requirement

The thalidomide disaster intensified scrutiny of pharmaceutical oversight. Frances Kelsey’s role in preventing U.S. marketing approval became an influential example of regulatory caution. In 1962, the Kefauver–Harris amendments strengthened drug regulation and required manufacturers to establish effectiveness before marketing. FDA’s chronology records this shift.

The distinction matters historically: evidence that a product could be tolerated was insufficient to establish that its claimed therapeutic purpose was justified. This development connects regulation with the history of clinical trials.

Monitoring medicines after introduction

Britain established the Yellow Card Scheme in 1964 following the thalidomide disaster. It collected reports of suspected adverse drug reactions to provide early warning of possible hazards. Its significance lay in making observations from ordinary medical use part of an organized safety system: regulatory responsibility continued after a medicine entered circulation.

The word ‘suspected’ is essential. Reporting a possible reaction initiates investigation; it does not by itself settle whether the medicine caused the event. The scheme’s own retrospective acknowledged limitations shared by spontaneous reporting systems while emphasizing their contribution to identifying previously unrecognized hazards.

Patient participation also changed the sources of regulatory knowledge. By its fiftieth anniversary, the scheme included direct patient reporting introduced in 2005, alongside professional and industry reports. The MHRA’s anniversary account describes this development. Patients increasingly contributed observations to safety assessment rather than appearing only as recipients of professional decisions.

International cooperation and pharmacovigilance

Medicine safety also became a subject of international cooperation. In 1963, the World Health Assembly called for systematic collection of information about serious adverse reactions, particularly after medicines became available for public use. The WHO Programme for International Drug Monitoring followed in 1968.

Participating countries contributed individual case safety reports to a shared international database. This approach made experience collected in different national settings available for detecting potential hazards. WHO describes pharmacovigilance as encompassing the detection, assessment, understanding and prevention of adverse effects and other medicine-related problems. Its purpose therefore extends beyond counting reports to interpreting evidence and supporting judgments about benefits and risks. The WHO programme history explains this institutional framework.

Historically, this represents an expansion of responsibility across borders. National regulation and international exchange became complementary activities, although the existence of a shared programme should not be mistaken for identical regulatory institutions or capabilities in every country.

Changing judgments and the limits of progress narratives

Safety judgments could change after approval. FDA’s historical exhibit describes how serious blood disorders associated with chloramphenicol prompted warnings, including a boxed warning in 1961. It also recounts the withdrawal of terfenadine after a safer alternative changed the assessment of its benefits relative to its risks. These examples show that regulatory history includes decisions about communicating hazards and reconsidering established products, as well as initial authorization. FDA’s therapeutic history exhibit supplies these cases.

Taken together, the episodes suggest a history of repeated reassessment rather than a steady march toward certainty. Questions about sufficient evidence, acceptable harm and effective communication persisted as institutions acquired new powers. This is an interpretation of the cases, not a claim that every jurisdiction followed the same sequence.

The sources used here are institutional retrospectives. They identify important events but also reflect the perspectives of the organizations preserving them. A fuller history would place these accounts alongside patient testimony, commercial records and contemporary legislative debates.

Sources and further reading